about
Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasisPneumococcal vaccine and patients with pulmonary diseasesCompliance with anti-H1N1 vaccine among healthcare workers and general populationNon-Intensive Care Unit Acquired Pneumonia: A New Clinical Entity?Nontuberculous Mycobacteria in Noncystic Fibrosis BronchiectasisManagement of bronchiectasis in adultsThe role of vaccination in preventing pneumococcal disease in adultsThe EMBARC European Bronchiectasis Registry: protocol for an international observational studyAcute myocardial infarction versus other cardiovascular events in community-acquired pneumoniaThe best of respiratory infections from the 2015 European Respiratory Society International CongressBronchiectasis and Aspergillus: How are they linked?Management of nontuberculous mycobacterial infection in the elderly.Acidemia does not affect outcomes of patients with acute cardiogenic pulmonary edema treated with continuous positive airway pressure.Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia.Thrombocytopenia and thrombocytosis at time of hospitalization predict mortality in patients with community-acquired pneumonia.Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis.Etiology of Non-Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity.The clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: a cohort of hospitalized patients.The management of community-acquired pneumonia in the elderlyHelmet continuous positive airway pressure vs oxygen therapy to improve oxygenation in community-acquired pneumonia: a randomized, controlled trial.Prulifloxacin: a brief review of its potential in the treatment of acute exacerbation of chronic bronchitisNon-invasive mechanical ventilation in patients with diffuse interstitial lung diseases.Towards tuberculosis elimination: an action framework for low-incidence countriesStrategic targets of essential host-pathogen interactions.Azithromycin and lower respiratory tract infections.Highlights on the appropriate use of fluoroquinolones in respiratory tract infections.Chlamydia pneumoniae and Mycoplasma pneumoniae.Severe asthma exacerbation: role of acute Chlamydophila pneumoniae and Mycoplasma pneumoniae infectionIntroducing a new HERMES project on respiratory infections.100 years of respiratory medicine: pneumonia.Telithromycin in lower respiratory tract infections.Chromogranin A levels and mortality in patients with severe sepsisChlamydophila pneumoniae.Characterizing Non-Tuberculous Mycobacteria Infection in Bronchiectasis.Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts.The bronchiectasis severity index. An international derivation and validation study.Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study.Microbiological diagnosis and antibiotic therapy in patients with community-acquired pneumonia and acute COPD exacerbation in daily clinical practice: comparison to current guidelines.Chlamydophila pneumoniae induces a sustained airway hyperresponsiveness and inflammation in mice.Antibiotics as immunomodulant agents in COPD.
P50
Q26739006-63403106-2758-453B-B339-DF423020CF4AQ26825944-A661D79A-5F33-4EB5-8FF9-406B146EFF98Q27002395-9FA970B1-7472-4236-AFED-740136B981F7Q28080078-53703F48-20EF-48AA-BC04-45A09E83C7BCQ28083865-311587B4-0962-49D6-9237-E2101391060FQ28087221-98B3E918-CAC0-403D-92A9-AF754F7A6EA1Q28396749-EA42B498-9C1A-409E-A18D-6EF7AC25A5D7Q28596688-4EED403F-31B0-49B4-AE0B-A72D28900E7EQ28596751-4982220A-B90D-4F04-8888-F1FD94CD8238Q28598393-4EA826FD-B4B8-4FAC-A5D7-25A5CD16CB3FQ30243947-45B2BAA9-2653-4129-9B89-09ACAE6978BAQ30406048-1AD6CB2A-D57F-4893-9963-CB855687FD7FQ33159403-E750DFFB-BA92-4B4E-8607-7DA582EDF25CQ33380109-DFF6625E-902E-4740-9F6B-536BD2B61E5FQ33386681-83CC0C00-C3C8-4CFD-BBB8-4451415E0469Q33586621-E877C54D-C884-4561-B6FF-95A831AD06DCQ33786085-255E1054-744B-4E11-A2D7-F4A85CCF6B96Q33817770-C46AECE9-DC94-49B2-BD6E-437BB9BD8837Q33915736-69517291-BA3A-4548-8AF9-3C21F1921580Q34098606-7DF726BE-5734-4395-95B6-D2651FDF245BQ34585467-36436346-0C4E-4DFB-8C6A-0ACC2C0D9641Q34728823-D9D8A38D-3531-4834-86D4-FE93B5E0F4E5Q35344151-5B68727D-7C21-4754-96E5-5AED88D7CA9DQ36064617-14AF0CDF-0FB4-485C-B77E-DE39FFA065EEQ36283753-B6E11CFB-E457-46BF-884A-4EAFF71B7FD6Q36323384-379E5D80-9ED4-4459-9D37-431B85572A5CQ36358387-29EFCB20-B3E3-4B6A-9F87-FE42D11AAD7DQ36731584-6B691F3D-AD3E-40C2-AC59-E6B1C2BB21F7Q36757974-80A3F4AB-8F67-4CED-A26C-21BD5D825A05Q36767305-0B308E3C-34FC-4BBF-9D62-F7C696E922E0Q36895727-1B293B02-C3C8-4F12-A7A3-B6C9330116F6Q37264816-D85F01A9-F047-447C-9B16-0E926D8E0B47Q37394182-65C1A639-0EF9-4216-9580-015A12B4CEA8Q37465667-9B894070-64DF-4126-AD75-C583D279962EQ37471610-1E15B18E-F6BD-43B2-BC71-B691D301C3C6Q37688482-4EB7B90E-0908-407B-A32A-A132175AD28AQ37725086-3D8EB10A-2B93-4892-8AD6-6C9599EB3D7CQ37846731-E0BA1842-8D8A-4D62-A544-558609F531A7Q37858665-D7D95BBA-4EE8-4028-BF91-CD7C61A8FBAAQ37982879-CFEF2A2E-3B96-47B7-9D49-AC6354BB462A
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Stefano Aliberti
@ast
Stefano Aliberti
@en
Stefano Aliberti
@es
Stefano Aliberti
@nl
Stefano Aliberti
@sl
type
label
Stefano Aliberti
@ast
Stefano Aliberti
@en
Stefano Aliberti
@es
Stefano Aliberti
@nl
Stefano Aliberti
@sl
prefLabel
Stefano Aliberti
@ast
Stefano Aliberti
@en
Stefano Aliberti
@es
Stefano Aliberti
@nl
Stefano Aliberti
@sl
P214
P244
P1053
K-9115-2016
P106
P1153
9247687000
P21
P214
P244
nb2014005495
P31
P3829
P496
0000-0002-0090-4531
P734
P735
P7859
lccn-nb2014005495